Sanofi-Astrazeneca preventive RSV drug recommended for approval by CHMP
![Photo: Benoit Tessier/Reuters/Ritzau Scanpix](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article14410667.ece/ALTERNATES/schema-16_9/20220728-073146-2-5954x3342ma.jpg)
On Friday, the European Medicines Agency’s (EMA) special committee, the CHMP, sent a preventive treatment for respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants one step closer to European market authorization.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Pfizer to submit RSV vaccine for FDA approval in fall
For subscribers
Pfizer initiates phase III of influenza vaccine candidate
For subscribers